Gilead Sciences Inc. cut the company’s 2020 revenue forecast, citing lower-than-expected demand and difficulty in predicting sales of remdesivir, the only treatment approved in the United States for patients hospitalized with Covid-19.

Shares of Gilead Sciences Inc. rose after the company’s antiviral drug remdesivir became the first approved treatment for Covid-19 in the United States.

Shares of Gilead Sciences jumped in trading following full approval for Veklury (remdesivir) as a treatment for Covid-19.

A row broke out over a World Health Organization (WHO) clinical trial which concluded that Gilead’s anti-viral drug remdesivir has little or no impact on a patient’s chances of surviving Covid-19.

Fujifilm Holdings Corp. said the company is seeking to have the flu drug Avigan approved in Japan as a treatment for Covid-19, a move that comes after a late-stage study showed reduced recovery times for patients with non-severe symptoms.

Gilead Sciences Inc.’s remdesivir had little or no effect on Covid-19 patients’ length of hospital stay or chances of survival, a clinical trial by the World Health Organization (WHO) found.

The European Union agreed to pay more than 1 billion euros ($1.2 billion) to Gilead for a six-month supply of the company’s antiviral drug remdesivir, shortly before the publication of final results for the largest trial of the Covid-19 medication.

In a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines, Covid-19 antibodies last at least three months and so do symptoms for many.

The U.S. National Institutes of Health is launching a clinical trial of a combination of Gilead Sciences’ antiviral drug remdesivir (Vitrakvy) and hyperimmune intravenous immunoglobulin (hIVIG).

Final data from Gilead Sciences Inc.’s antiviral drug remdesivir showed the treatment cut Covid-19 recovery time by five days compared with patients who got a placebo, one day faster than indicated in preliminary data, the company and researchers said.